Risk Factors and Immunity in a Nationally Representative Population following the 2009 Influenza A(H1N1) Pandemic

被引:86
作者
Bandaranayake, Don [1 ]
Huang, Q. Sue [1 ]
Bissielo, Ange [1 ]
Wood, Tim [1 ]
Mackereth, Graham [2 ]
Baker, Michael G. [3 ]
Beasley, Richard [4 ]
Reid, Stewart [5 ]
Roberts, Sally [6 ]
Hope, Virginia [1 ]
机构
[1] Natl Ctr Biosecur & Infect Dis, Inst Environm Sci & Res, Upper Hutt, New Zealand
[2] Minist Hlth, Wellington, New Zealand
[3] Univ Otago, Wellington Sch Med, Wellington, New Zealand
[4] Wellington Hosp, Med Res Inst New Zealand, Wellington, New Zealand
[5] Ropata Med Ctr, Lower Hutt, New Zealand
[6] Auckland Dist Hlth Board, Dept Microbiol, Auckland, New Zealand
来源
PLOS ONE | 2010年 / 5卷 / 10期
关键词
A H1N1; ANTIBODY; VIRUS; INFECTION; VACCINE; VOLUNTEERS; PROTECTION; CHALLENGE; SERUM;
D O I
10.1371/journal.pone.0013211
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Understanding immunity, incidence and risk factors of the 2009 influenza A(H1N1) pandemic (2009 H1N1) through a national seroprevalence study is necessary for informing public health interventions and disease modelling. Methods and Findings: We collected 1687 serum samples and individual risk factor data between November-2009 to March-2010, three months after the end of the 2009 H1N1 wave in New Zealand. Participants were randomly sampled from selected general practices countrywide and hospitals in the Auckland region. Baseline immunity was measured from 521 sera collected during 2004 to April-2009. Haemagglutination inhibition (HI) antibody titres of >= 1:40 against 2009 H1N1 were considered seroprotective as well as seropositive. The overall community seroprevalence was 26.7% (CI: 22.6-29.4). The seroprevalence varied across age and ethnicity. Children aged 5-19 years had the highest seroprevalence (46.7%; CI: 38.3-55.0), a significant increase from the baseline (14%; CI: 7.2-20.8). Older adults aged >= 60 had no significant difference in seroprevalence between the serosurvey (24.8%; CI: 18.7-30.9) and baseline (22.6%; CI: 15.3-30.0). Pacific peoples had the highest seroprevalence (49.5%; CI: 35.1-64.0). There was no significant difference in seroprevalence between both primary (29.6%; CI: 22.6-36.5) and secondary healthcare workers (25.3%; CI: 20.8-29.8) and community participants. No significant regional variation was observed. Multivariate analysis indicated age as the most important risk factor followed by ethnicity. Previous seasonal influenza vaccination was associated with higher HI titres. Approximately 45.2% of seropositive individuals reported no symptoms. Conclusions: Based on age and ethnicity standardisation to the New Zealand Population, about 29.5% of New Zealanders had antibody titers at a level consistent with immunity to 2009 H1N1. Around 18.3% of New Zealanders were infected with the virus during the first wave including about one child in every three. Older people were protected due to pre-existing immunity. Age was the most important factor associated with infection followed by ethnicity. Healthcare workers did not appear to have an increased risk of infection compared with the general population.
引用
收藏
页数:9
相关论文
共 31 条
[1]  
[Anonymous], 2010, EURO SURVEILL
[2]  
[Anonymous], 2009, EURO SURVEILL
[3]   A Hybrid Model for a Hybrid Science [J].
Baker, Jim .
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2009, 1 (01) :1-1
[4]  
*CDC, 2009, MMWR-MORBID MORTAL W, V58, P435
[5]  
CHAN M, 2009, SWINE INFLUENZA STAT
[6]   Seroprevalence of Antibodies to Pandemic (H1N1) 2009 Influenza Virus Among Hospital Staff in a Medical Center in Taiwan [J].
Chan, Yu-Jiun ;
Lee, Chia-Ling ;
Hwang, Shinn-Jang ;
Fung, Chang-Phone ;
Wang, Fu-Der ;
Yen, David H. T. ;
Tsai, Cheng-Hsien ;
Chen, Yi-Ming Arthur ;
Lee, Shou-Dong .
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2010, 73 (02) :62-66
[7]   2009 Influenza A(H1N1) Seroconversion Rates and Risk Factors Among Distinct Adult Cohorts in Singapore [J].
Chen, Mark I. C. ;
Lee, Vernon J. M. ;
Lim, Wei-Yen ;
Barr, Ian G. ;
Lin, Raymond T. P. ;
Koh, Gerald C. H. ;
Yap, Jonathan ;
Cui, Lin ;
Cook, Alex R. ;
Laurie, Karen ;
Tan, Linda W. L. ;
Tan, Boon Huan ;
Loh, Jimmy ;
Shaw, Robert ;
Durrant, Chris ;
Chow, Vincent T. K. ;
Kelso, Anne ;
Chia, Kee Seng ;
Leo, Yee Sin .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (14) :1383-1391
[8]  
de Jong J C, 2003, Dev Biol (Basel), V115, P63
[9]   Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City [J].
Garcia-Garcia, Lourdes ;
Luis Valdespino-Gomez, Jose ;
Lazcano-Ponce, Eduardo ;
Jimenez-Corona, Aida ;
Higuera-Iglesias, Anjarath ;
Cruz-Hervert, Pablo ;
Cano-Arellano, Bulmaro ;
Garcia-Anaya, Antonio ;
Ferreira-Guerrero, Elizabeth ;
Baez-Saldana, Renata ;
Ferreyra-Reyes, Leticia ;
Ponce-de-Leon-Rosales, Samuel ;
Alpuche-Aranda, Celia ;
Henry Rodriguez-Lopez, Mario ;
Perez-Padilla, Rogelio ;
Hernandez-Avila, Mauricio .
BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 :847
[10]  
Gargiullo P., 2009, Morbidity and Mortality Weekly Report, V58, P1241